Lupron Depot 22.5
FDA Approves New Drug Xofigo for Advanced Prostate Cancer »
"The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for"...
Read the FDA Approves New Drug Xofigo for Advanced Prostate Cancer article »
Lupron Depot 22.5
PATIENT INFORMATION
An information pamphlet for patients is included with the product.
Last reviewed on RxList: 6/2/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Lupron Depot 22.5 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.
Updated & New
